| ❗FDA APPROVAL COULD SEND THIS STOCK SOARING (ad) |
|
| Protect Your Investments from Global Conflict (ad) |
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Here's how you can invest >>> |
|
 Apple Inc. (AAPL)    Amazon.com, Inc. (AMZN)   Barker Minerals Ltd (BML) - No Headlines, Ratings, Earnings Results, Dividends, Insider Trades, Options Activity, Company Press Releases or Headlines Today
 Meta Platforms, Inc. (META)  - CEO Mark Zuckerberg sold 31,493 shares of the company's stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $492.14, for a total transaction of $15,498,965.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
- CEO Mark Zuckerberg sold 77,412 shares of the business's stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $504.82, for a total transaction of $39,079,125.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
- insider Jennifer Newstead sold 585 shares of the company's stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $505.29, for a total value of $295,594.65. Following the sale, the insider now owns 39,568 shares in the company, valued at approximately $19,993,314.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
- (3/28) Is a Platform Also a Product? One New York Court Says Yes, and It's Not Alone (law.com)
- (3/28) Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages (marketbeat.com)
- (3/28) Meta, Snapchat and TikTok sued by Ontario schools (proactiveinvestors.com)
- (3/28) Meta Platforms, Inc. (NASDAQ:META) Insider Sells $295,594.65 in Stock (insidertrades.com)
- (3/28) Big tech outperformance coming to an end, says broker (proactiveinvestors.com)
- (3/27) Insider Selling: Meta Platforms, Inc. (NASDAQ:META) Insider Sells 585 Shares of Stock (marketbeat.com)
- (3/27) Making Sense of the Earnings Picture (zacks.com)
- (3/27) Meta employee calls out company for limiting staff's free speech (msn.com)
 Microsoft Co. (MSFT)  - Allstate (NYSE:ALL) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $190.00 price target on the stock, up previously from $158.00. This represents a 10.0% upside from the current price of $172.77.
- Estée Lauder Companies (NYSE:EL) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $170.00 price target on the stock, up previously from $160.00. This represents a 10.6% upside from the current price of $153.69.
- Kimberly-Clark (NYSE:KMB) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $150.00 price target on the stock, up previously from $133.00. This represents a 15.7% upside from the current price of $129.60.
- Lands' End (NASDAQ:LE) was upgraded by analysts at Craig Hallum from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock, up previously from $9.00. This represents a 37.9% upside from the current price of $10.88.
- MAG Silver (NYSEAMERICAN:MAG) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $13.50 price target on the stock. This represents a 32.1% upside from the current price of $10.22.
- Omnicom Group (NYSE:OMC) was upgraded by analysts at BNP Paribas from a "neutral" rating to an "outperform" rating. They now have a $115.00 price target on the stock. This represents a 18.3% upside from the current price of $97.20.
- The PNC Financial Services Group (NYSE:PNC) was upgraded by analysts at HSBC Holdings plc from a "reduce" rating to a "hold" rating. They now have a $155.00 price target on the stock, up previously from $141.00. This represents a 3.6% downside from the current price of $160.71.
- Public Storage (NYSE:PSA) was upgraded by analysts at Raymond James from a "market perform" rating to a "strong-buy" rating. They now have a $330.00 price target on the stock. This represents a 14.2% upside from the current price of $289.09.
- Triumph Group (NYSE:TGI) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $18.00 price target on the stock. This represents a 17.3% upside from the current price of $15.34.
- Millicom International Cellular (NASDAQ:TIGO) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating.The current price is $20.35.
- U.S. Bancorp (NYSE:USB) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $53.00 price target on the stock, up previously from $47.00. This represents a 18.6% upside from the current price of $44.69.
- Vornado Realty Trust (NYSE:VNO) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $26.00 price target on the stock, up previously from $24.00. This represents a 9.3% downside from the current price of $28.66.
- View today's most recent analysts' upgrades at MarketBeat.com
| The Tiny Biotech Behind a Cancer "Smart Bomb" (ad) |
There's a new cancer treatment so precise, it's been called a "smart bomb."
One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
Get the full story here >>> |
|
- Molina Healthcare (NYSE:MOH) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating. They now have a $439.00 price target on the stock. This represents a 6.6% upside from the current price of $411.97.
- Palantir Technologies (NYSE:PLTR) was downgraded by analysts at Monness Crespi & Hardt from a "neutral" rating to a "sell" rating. They now have a $20.00 price target on the stock. This represents a 14.3% downside from the current price of $23.35.
- Construction Partners (NASDAQ:ROAD) was downgraded by analysts at Sidoti from a "buy" rating to a "neutral" rating. They now have a $59.00 price target on the stock. This represents a 4.4% upside from the current price of $56.53.
- View today's most recent analysts' downgrades at MarketBeat.com
| U.S. Prepares for Chinese "Invasion" (ad) |
|
- ADC Therapeutics (NYSE:ADCT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $11.00 price target on the stock. This represents a 124.0% upside from the current price of $4.91.
- Amgen (NASDAQ:AMGN) is now covered by analysts at Raymond James. They set a "market perform" rating on the stock.The current price is $285.63.
- Aquestive Therapeutics (NASDAQ:AQST) is now covered by analysts at Raymond James. They set an "outperform" rating and a $7.00 price target on the stock. This represents a 58.0% upside from the current price of $4.43.
- Bentley Systems (NASDAQ:BSY) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.The current price is $52.53.
- CyberArk Software (NASDAQ:CYBR) is now covered by analysts at BTIG Research. They set a "buy" rating and a $317.00 price target on the stock. This represents a 18.4% upside from the current price of $267.64.
- enGene (NASDAQ:ENGN) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $37.00 price target on the stock. This represents a 117.9% upside from the current price of $16.98.
- Global Net Lease (NYSE:GNL) is now covered by analysts at Truist Financial Co.. They set a "hold" rating and a $7.00 price target on the stock. This represents a 9.7% downside from the current price of $7.75.
- Grindr (NYSE:GRND) is now covered by analysts at TD Cowen. They set a "buy" rating and a $12.00 price target on the stock. This represents a 21.8% upside from the current price of $9.85.
- Immunovant (NASDAQ:IMVT) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $50.00 price target on the stock. This represents a 56.9% upside from the current price of $31.87.
- Jasper Therapeutics (NASDAQ:JSPR) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $70.00 price target on the stock. This represents a 133.0% upside from the current price of $30.04.
- Merus (NASDAQ:MRUS) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $69.00 price target on the stock. This represents a 53.8% upside from the current price of $44.85.
- Progress Software (NASDAQ:PRGS) is now covered by analysts at DA Davidson. They set a "buy" rating and a $65.00 price target on the stock. This represents a 23.1% upside from the current price of $52.80.
- SI-BONE (NASDAQ:SIBN) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock. This represents a 49.3% upside from the current price of $16.75.
- Scholar Rock (NASDAQ:SRRK) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $30.00 price target on the stock. This represents a 83.0% upside from the current price of $16.39.
- TruBridge (NASDAQ:TBRG) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $13.00 price target on the stock. This represents a 34.6% upside from the current price of $9.66.
- TransMedics Group (NASDAQ:TMDX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $95.00 price target on the stock. This represents a 23.6% upside from the current price of $76.89.
- Veru (NASDAQ:VERU) is now covered by analysts at Raymond James. They set an "outperform" rating and a $3.00 price target on the stock. This represents a 308.2% upside from the current price of $0.74.
- Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $5.00 price target on the stock. This represents a 123.2% upside from the current price of $2.24.
- View today's most recent analysts' new coverage at MarketBeat.com
| Get 30 Days of MarketBeat All Access Free | | Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: |
| - Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. - Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. - Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
| START YOUR 30-DAY FREE TRIAL  |
|
| Upgrade Your Subscription |
Upgrade to MarketBeat All Access and receive your premium edition of MarketBeat Daily at 9:00 AM ET. | UPGRADE NOW |
|
View and add up to five holdings to your watchlist.
| VIEW MY PORTFOLIO |
|
Join MarketBeat's free stock discussion and trading idea group on Facebook.
| JOIN NOW |
|
Thank you for subscribing to MarketBeat! We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that's you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com. If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails. © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103 . United States. Today's Bonus Content: With the "Bitcoin Loophole" you can supercharge the gains by 10x or more! (Click to Opt-in)  |
|
No comments:
Post a Comment